CEACAM5 and neoplasm: As expected, CEA-TCB monotherapy and CEA-TCB plus anti-PD-L1 combination therapy led to increased CD8 T cell numbers and decreased tumor burden, indicating control of tumor growth by the immune system (50, 79).